Back to top
more

Werewolf Therapeutics (HOWL)

(Delayed Data from NSDQ)

$0.88 USD

0.88
11,983,028

+0.01 (1.12%)

Updated Aug 24, 2026 04:00 PM ET

After-Market: $0.88 0.00 (-0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (149 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake

by Zacks Equity Research

INSM shares jump 16% as Brinsupri's strong debut offset wider Q3 losses, lifting revenue 52% year over year.

Zacks Equity Research

Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised

by Zacks Equity Research

ALKS tops Q3 earnings and revenue estimates as Vivitrol, Aristada and Lybalvi fuel growth; 2025 guidance raised after strong demand.

Zacks Equity Research

BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy

by Zacks Equity Research

BMRN tops Q3 earnings expectations but misses on sales. The company moves to divest its hemophilia gene therapy, Roctavian.

Zacks Equity Research

Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil

by Zacks Equity Research

VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.

Zacks Equity Research

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Zacks Equity Research

XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

XOMA Royalty (XOMA) delivered earnings and revenue surprises of +500.00% and +39.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Beyond Air (XAIR) delivered earnings and revenue surprises of -2.00% and -1.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of +40.00% and +7.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?